Recruiting
Phase 2

Daratumumab with STK11

Sponsor:

NYU Langone Health

Code:

NCT05807048

Conditions

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Daratumumab and Hyaluronidase-fihj

Pre-Intervention Medication

Post-Intervention Medication

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-13. This information was provided to ClinicalTrials.gov by NYU Langone Health on 2025-03-12.